Haemaccel is used to provide supportive symptomatic relief in acute conditions, such as circulatory failure resulting from significant blood or fluid loss. This includes conditions presenting with acute episodes of volume depletion, such as hypovolemic shock.

This therapeutic support is relevant in contexts involving heightened systemic burden, such as managing severe fluid loss due to extensive burns, complications from major haemorrhage, and perioperative fluid deficits during major surgery. The intervention plays a role in managing symptoms such as low blood pressure (hypotension) and compensatory rapid heart rate (tachycardia) that occur during circulatory distress.

“It provides support that helps manage the systemic load of acute circulatory distress.”

Haemaccel is used when supportive symptom management is appropriate in situations involving temporary physiological imbalance. This assists with maintaining physiological stability when symptoms are prominent during medical interventions, supporting the body during periods of heightened physical stress.

---

Quick Fact: Relief for Hypotension

This medicine is intended for managing symptoms related to low blood pressure that occurs due to a lack of sufficient circulating blood volume.

Regulatory References

1. Summary of Product Characteristics (SmPC) from the Irish Health Products Regulatory Authority

Haemaccel is a plasma volume expander whose use is strictly governed by regulatory eligibility criteria based on patient risk factors. The medicine is contraindicated and must not be used in individuals with a known hypersensitivity to the preparation’s constituents, such as Polygeline, or in patients with existing anaphylactoid reactions.

Use of Haemaccel is restricted or requires special caution in several populations. This includes patients with underlying conditions where an increase in circulating blood volume or fluid retention poses a special risk. Such conditions include congestive heart failure, uncontrolled hypertension, pulmonary oedema, and severe kidney failure like renal and post-renal anuria. It is also restricted in patients with haemorrhagic diathesis or those at an increased risk of histamine release.

Regarding age, Haemaccel is primarily intended for adult use, with pediatric use requiring close medical supervision. For pregnancy, use is conditional: it may be administered for volume replacement only if blood is not available, following a careful risk assessment. Regulatory information regarding its use during breastfeeding is not available.

The official documentation for Haemaccel (Polygeline) describes specific interaction patterns that are classified primarily as physical incompatibility and pharmacodynamic reinforcement. No specific pharmacokinetic interactions involving CYP enzymes or drug transporters are formally documented.

Incompatible Combinations and Administration Rules

Direct administration of Haemaccel with citrated blood (such as stored blood) is officially prohibited. This is classified as a physical incompatibility because the calcium ions present in Haemaccel can cause the citrated blood to coagulate or clot. When these products are administered sequentially, regulatory documents mandate that the infusion set must be adequately flushed between the two products to prevent residual mixing. Furthermore, the product must not be mixed with any other medicinal product in the infusion solution when specific compatibility data are absent.

Pharmacodynamic Reinforcement

Caution is required when co-administering Haemaccel with certain medications due to the potential for pharmacodynamic reinforcement:

• Cardiac Glycosides: Co-administration with cardiac glycosides (e.g., Digoxin) is officially associated with an increased risk of digitalis toxicity. This is a documented outcome linked to the calcium content of the solution.
• Histamine-Releasing Drugs: The potential for Haemaccel to cause histamine release leads to a risk of cumulative anaphylactoid effects (such as a drop in blood pressure or skin reactions) when used alongside other histamine-releasing drugs (including certain anaesthetics and muscle relaxants).

Colloid Osmosis and Intravascular Volume Expansion

The primary mechanism of Haemaccel involves colloid osmotic pressure (COP). The large Polygeline molecules, when infused, remain confined to the intravascular space by the capillary walls, exerting an osmotic force that draws fluid from the tissues into the bloodstream. This action directly and rapidly results in intravascular volume expansion.

---

Hemodynamic Stabilization Cascade

The physical volume expansion initiates a systemic hemodynamic cascade. The increased fluid volume immediately boosts the blood returning to the heart (preload), which subsequently enhances the heart's cardiac output. This cascade increases arterial blood pressure and facilitates systemic flow to tissues. The concurrent hemodilution also reduces blood viscosity, which modifies flow characteristics in the microcirculation.

---

Physiological Constraints and Non-Specific Effects

While primarily osmotic, the mechanism has limitations. Polygeline can trigger the non-immunological release of endogenous histamine from mast cells, which may lead to temporary, counter-regulatory vasodilation. Additionally, the mechanism physically dilutes clotting factors and platelets, temporarily reducing hemostatic competence.

Instruction Map: How to use Haemaccel — Administration Overview

Haemaccel is an intravenous colloidal plasma substitute whose usage is dictated by the acute need for volume replacement.

---

Administration Scope

Feature	Instruction
Route of administration	Intravenous Infusion only.
Dosing schedule	The volume is typically determined by the estimated blood loss. The initial volume for hypovolaemic shock is generally 500 ml to 1,000 ml. Doses for burn patients are calculated based on body weight and percent surface area burned over a 24-hour period.
Timing in relation to meals (if applicable)	Not applicable.
Preparation requirements (if applicable)	Supplied as a ready-to-use solution that requires no dilution.
Age-group administration rules	Volume replacement principles are prioritized over distinct dosage adjustments for older adults or pediatric patients.
Missed-dose rules	Not applicable; usage is for acute, on-demand replacement.
Special procedural conditions	The infusion solution is ideally warmed to body temperature prior to administration, though it may be given at ambient temperature in emergencies. The volume is adjusted based on clinical response and parameters such as urine output.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Intravenous (Parenteral)
Frequency pattern	As-needed (for acute episodes) or Scheduled (e.g., for specific management phases in burn cases)
Basis of use	Plasma volume substitution.
Use-context constraints	Administration is monitored in a clinical setting; volume titration is managed to ensure Haematocrit does not fall below 25%.

---

Resulting Procedural Structure

Step sequence:

• Administer the ready-to-use solution via Intravenous Infusion.
• Infuse at a rate determined by the clinical condition, with 500 ml typically given in no less than 60 minutes.
• The solution must NOT be mixed with citrated blood in the same infusion set, as the calcium content may cause clotting.

Connection to the overall use protocol (2–4 sentences): The protocol establishes the use of this solution as an acutely administered intervention where volume and infusion rate are continuously monitored and adjusted based on physiological response. This sequence defines a necessary restriction on mixing the product with specific blood products, ensuring the standardized administration of the solution for plasma volume restoration.

Research evidence / Overview of Studies for Haemaccel

Evidence for Volume Replacement in Acute Hypovolemic Shock

Research has examined Haemaccel's role as a subject of fluid replacement research for conditions associated with acute or disruptive episodes where significant fluid or blood loss causes circulatory strain, such as hypovolemic shock. The evidence base includes prospective, multicentric observational studies and various older comparative trials. These studies generally tracked short-term outcomes monitoring physiological strain or stress in adults who were experiencing trauma or other causes of volume depletion.

The findings describe patterns observed in the studies related to the immediate maintenance or change in vital signs, such as systolic blood pressure and heart rate, which were measurements tracked by researchers. Researchers also reported how symptoms evolved in the observed populations by documenting levels of certain blood chemicals like lactate, and measuring physical markers of perfusion such as urine output. These results apply only to the populations studied and primarily reflect the acute response within the first few hours or the first day after administration, providing insight into short-term changes only.

Evidence for Managing Fluid Needs During Surgery

The research explored the use of Haemaccel for providing volume support in patients undergoing planned surgical procedures where fluid deficits may occur. These investigations typically include small-scale Randomized Controlled Trials (RCTs) and controlled clinical studies, often comparing it to crystalloid solutions. Studies were conducted during periods of increased symptom activity (the perioperative phase) and focused on outcomes related to systemic or functional imbalance.

Long-Term Research and Follow-up Durations

The available body of evidence primarily focuses on episodes where symptoms become more noticeable, meaning the immediate, acute stabilization phase following an event like trauma or surgery. Most clinical trials and observational studies research explores short-term symptom changes, with follow-up follow-up durations were limited to the hours or first day after the infusion. Consequently, long-term effects are not fully established. The research contributes to the evidence base by describing acute physiological responses, but certainty remains low regarding outcomes measured beyond the immediate hospital stay.

Key Limitations and Areas of Uncertainty

Evidence quality is influenced by studies relying on observational settings evaluating daily-life functioning or older trial methodologies. A key limitation is that sample sizes were modest in many of the controlled trials that compared Haemaccel to other fluid solutions. Comparative evidence is lacking when placing the product against some newer colloidal plasma expanders currently on the market. Research provides context about group findings, and the body of evidence highlights what is known—and what is still uncertain regarding its overall profile and long-term implications.

Key Studies & References

1. Polygeline in patients with hypovolemia caused by accidental trauma: a prospective, multicentric, safety study
2. Haemaccel 3.5% w/v solution for infusion - Summary of Product Characteristics (SPC)

Common questions about Haemaccel (FAQ)

Q: Does Haemaccel contain high levels of sodium?

A: Official product information notes that the solution contains sodium chloride, and this is a factor for patients on a controlled sodium diet to consider, as indicated in the warnings. This detail is included in the official labeling to ensure appropriate clinical oversight.

---

Q: What is the potassium content of Haemaccel?

A: The official labeling indicates that the solution contains potassium chloride. This is also noted in the official product information as a factor for patients on a controlled potassium diet to consider when the product is administered.

---

Q: Can Haemaccel affect the balance of calcium in the blood?

A: Haemaccel contains calcium ions. Official warnings indicate that the calcium content, particularly when a large volume of the product is administered, could cause a slight and temporary increase in the concentration of blood calcium. However, official safety data has not documented clinical signs of hypercalcaemia (abnormally high calcium levels) related to its use.

---

Q: What happens if Haemaccel is mixed with a solution containing calcium?

A: Official regulatory documents state that Haemaccel is prohibited from being mixed with citrated blood (blood containing citrate) in the same set, because the calcium may cause clotting. The product information describes its compatibility with certain common solutions like Ringer's. For other medications, official guidelines require that specific compatibility data be verified before mixing.

---

Q: What is the molecular weight of Polygeline, the main substance in Haemaccel?

A: The primary active substance, Polygeline, is a gelatin derivative whose molecules have a mean molecular weight of 30,000 Dalton. This specific size is a physicochemical property that helps the substance remain in the bloodstream to achieve its volume-expanding effect.

---

Q: Is Haemaccel a type of colloid, and how is it different from Dextrans or HES solutions?

A: Haemaccel is officially classified as a colloidal plasma volume expander and specifically a gelatin derivative. Official regulatory documents describe its own properties, such as being iso-oncotic (having the same osmotic pressure) with plasma. The official label does not contain a direct comparison detailing how it differs from specific Dextran or HES solutions.

---

Q: Does Haemaccel contain any component derived from animals?

A: The active substance, Polygeline, is a modified fluid gelatin derivative. Official pharmaceutical information notes that gelatin used in these types of products is typically sourced from bovine collagen.

---

Q: What is the average duration of the volume-expanding effect of Haemaccel?

A: Official pharmacokinetic information states that Haemaccel has a relatively short-term volume-expanding effect. The substance has a mean half-life of about 5 hours in the body, meaning half of the amount is removed or metabolized in that time.

---

Q: How long does the body typically take to get rid of Haemaccel?

A: The body primarily gets rid of Haemaccel through the kidneys. Pharmacokinetic studies indicate that approximately 74% of the substance is excreted within four days of administration. The remaining substance is metabolized into smaller fragments, like peptides and amino acids, by enzymes.

---

Q: Does Haemaccel interfere with standard blood typing or cross-matching procedures?

A: According to official product descriptions of its pharmacological properties, Haemaccel does not interfere with standard hospital procedures for blood typing or cross-matching tests.

---

Q: Is Haemaccel used to provide fluid for an insulin injection, as described in some documents?

A: Yes, regulatory indications for Haemaccel state that it is officially used as a carrier solution for insulin. This is one of the specific uses permitted by the official documents and confirmed in regulatory labeling.

---

Q: Is the process by which Haemaccel is broken down in the body well understood?

A: Official information on how the drug is broken down (metabolism) indicates that the Polygeline substance is broken down into smaller peptides and amino acids. This process is carried out by proteolytic enzymes (enzymes that break down proteins) within the body.

---

Q: Does Haemaccel contain preservatives that could cause sensitivity?

A: Official product labeling explicitly states that Haemaccel contains no preservatives. The product is designated for single use, and the regulatory storage requirements address the disposal of any unused solution.

How to Store and Dispose of Haemaccel

Haemaccel solution must be stored strictly according to official regulatory guidelines to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C; Do not freeze.
Protection	No special precautions for light or moisture are specified.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The product is designated for single use only. Any portion of the Haemaccel solution remaining in the bottle after infusion must be discarded immediately. Before use, the solution must be checked; do not use if the seal is broken or the contents are cloudy.

All unused or expired product and related waste materials must be disposed of in accordance with local pharmaceutical waste requirements.